Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How did the CFO do with his Nov podcast?
He said:
UK rev's would begin late Q1 or early Q2 2022 - Grade: FAILURE
Topline growth begins end of Jan 2022 - in his own words Q1 was dismal - Grade: FAILURE
Hiring a focused sales team - Grade: FAILURE
New Distribution model domestically and int'l Grade: FAILURE
So far the CFO is almost as bad as the CEO. So how wrong are the rest of his predictions??
O&G revs expected late Q3 early Q4
Cannabis expected late 2022
Ag no time table but lagging Cannabis
With all this slop above, $5m revs for 2022? LMAO!!!
PCTL #1 on the “Wish I Sold” Board!!
It may have been given to the employee that filled the 4 gallons of Koolaide for Maverick.
Astute investors recognized the shenanigan's going on at PCT and exited.
Others continue to believe the fairy tales, even after years of total failure and their share value wiped out
Imagine the thought of a low tier, sub penny stock with a goof ball CEO wouldnt dare cross the line to pick up a few sheckles lol
The things I read here lol
Maybe the forklift but all the other equipment and machines at PCTL are worthless
Did the 8k describing the acquisition of fluid cleaning co or Nigerian cash infusion or the formation of the subsidiary print yet? I can’t find any recently filed anything for PCTL?
Now it’s embezzlement? LOL!!!
What’s next, stolen property? Hilarious…
PCTL quietly handing off somewhere around $50,000.oo worth stock for $250.oo and paying $15,000.oo cash to an unknown undisclosed “consult” while producing nothing and not receiving anything return is a gross misuse of company funds, likely embezzlement or pay for illegal or noncompliance affairs.
I asked PCTL what it was for & never got an answer....
Yes, everything PCTL does is underhanded, lol…
Prove it…
Yes - hush money, payoff, kickback. Or second maybe more likely suspicion is Market Maker Payolla
Its almost 4 years since someone from PCT filed a Form 3 or 4
We know the CEO was granted 10-15m shares per his employment agreement, let alone what else has been granted
Funny thing. If the CEO didnt file Form 4 for the millions of shares he acquired via employment agreement, then how many shares has he sold without filing Form 4??
Appears to be a pattern of deception at PCT, doesnt it
Not so far fetched
I do recall PCTs PR about above market convertible notes to RBC.. What the PR neglected to mention was the contingency of those notes was RBC acquiring aged debt which PCT promptly restructured as convertible at $0.001/sh
The history of deception is there so I would put nothing past this CEO or his worthless, rubber stamp BODs
Hush money? LOL!!!!!
In all seriousness- My thoughts are it’s likely hush money to keep an employee or partner from blowing the whistle on him. It’s an extraordinarily large amount of money for undisclosed consulting and and ridiculously discounted dispersement of shares. The secrecy and ambiguity and lies are at full throttle
Wonder who the consultant was, another family member or pal of the CEO?
PCTL is all over it with plenty .0001¢ shares to give away and years more testing to do in those oil fields with imaginary Nigerians. Let us Just keep believing
Has the Nigerian 9 Dollar infusion filing been listed yet? Tia
Zzzzz Another 3 1/2 Gallons of Nanobuble Koolaide
Some info on oil wells in Missouri:
'According to Missouri's Ministry of Natural Resources website well data, there are currently only 1022 active wells as of 15 March 2021. 253 of the 1022 wells have a depth of less than 400 ft, 599 wells have a depth between 400 ft to 800 ft while the rest have an average depth of 800 feet to 1800 feet. Only 18 wells have a depth of more than 1800 feet [3]. Southwest Missouri heavy oil has an API gravity of 17- 21.[5] The viscosity of the crude oil ranges between 1000 and 10000 cp. It also contains 14.8 percent asphaltene. The average well depth is 150 ft to 250 ft, porosity is 23.5 %, permeability is around 375 md, the reservoir pressure is 50 Psi and temperature is 50 oF.'
Quote from Muhammad Ali
Research Fellow @ Missouri University of Science and Technology
---------------------------------------------------------------------------------------------------
Brad Kramer is the owner of Kansas Resources Exploration and Development. The company manages oil wells in Kansas and Missouri and is the largest producer in Missouri, accounting for more than half of 2021's oil production.
Kramer said Missouri's production levels are not because of regulatory restraints.
"From the time I file a permit to drill, you're probably talking less than one week to have it approved," he said. "There are sites to drill. Regulation is not an issue. It's just, frankly, having the money to go do it. It's what's holding back most people that are in this area that I know."
The type of oil in Missouri is also different than the kind found in other states. Missouri's oil is found much shallower in the ground.
"The wells aren't as deep and so the product tends to be heavier," Steele said. "It's just harder to get out of the ground, costs more money. And that's the biggest reason why we aren't seeing higher levels of production right now in the state."
Kramer noted that smaller producers struggle to collect capital to invest in new drilling operations, which limits how fast expansion can happen.
Steele said Missouri production used to be more robust than it is now.
"You can kind of look at the production over time in Missouri, and it's declined, along with energy prices declining," Steele said. "So, given the energy and price increases over the last few weeks, we have seen a few producers that are starting to open up some shut-in wells."
Still haven’t seen any proof that the $8M influx has happened.
Gary would be blabbing to no end if that would have taken place.
Many of the die hard longs have even quit posting, situation is getting dire.
jobyn hard to convince someone with the facts when they have already incorrectly made up their mind otherwise!!
Internal Revenue Service rules treat the expiration of a stock option as equivalent to a sale of the option for zero dollars on the date it expired unexercised.
https://finance.zacks.com/can-claim-loss-unexercised-stock-options-1177.html
And it’s not a taxable event until the options are exercised…
Professionals understand the facts as the second example clearly demonstrates. No mention about exercising the option
Simply the issuance of stock options below fair market value is a taxable event. Simple
There are books and info available online to help clear up any confusion.
Thanks for letting clear the record beyond any doubt.
Only when exercised, thanks for proving my point, lol…
No, I’m right, and proven in your post…
Another Red Day Only.007 to Zero! How’s the QB listing working out
Here, maybe this provides a better understanding of those stock options PCT issued well below market
Sorry but youre 100% WRONG
Dont need to check with an accountant, been through it dozens of times with experts
Here, maybe this simple illustration can shed some light
Gary left you holding the Nigerian Bag! What a sham
No, I’m right, talk to a CPA…
If the options never get exercised (expire worthless), there is no taxable event…
There’s only a taxable event if the options get exercised. If shares were issued, then it would be a taxable event…
That consultant incurred a taxable event when accepting those options with an exercise price of only .0001
Before going further, what an outrage PCT would issue options to a consultant with an exercise price of .0001.. What kind of scam is going on there?
Back to the taxable event. Those options were well below fair market value when issued. Therefore, the holder is required to pay taxes on those options for ordinary income of appx $50,000
This must be followed up on and reported
PCTL does a remarkably good job at paying family and friends and washing money;
On March 1, 2021, the Company entered into a consulting agreement. Pursuant to the agreement, the consultant will provide consulting services to the Company in various marketing and management matters for a period of three months. In consideration for the services performed by the consultant, the Company agreed to compensate the consultant $5,000 per month. The Company also granted stock options to purchase 2,500,000 common shares exercisable at $0.0001 per share for one year. The options expired in full without exercise on March 1, 2022.
https://sec.report/Document/0001554795-22-000189/
Name anything this company has ever made good on...nothing..just promises and bs..Now they dangle a new carrot.....Nigerian gas and oil..Incidentally...a huge amount of internet scams online originate out of NIgeria...
This is yet another one.
Really quite hilarious that anyone can still support this scam of a company.
As Auctus alleges, PCT consented to and approved the exercise of appx 3m warrants in Dec 2021. OUCH!!
That alleged action could be an acknowledgment by PCT that Auctus had the rights and ownership of those warrants. This is a serious miscalculation by PCT, if this is what happened.
Also, only the fact PCT breached their agreement by not having sufficient shares available to facilitate the issuance. That smells to me as a weak plot to purposely keep their shares tied up to circumvent their obligation to Auctus and others.
Good luck Mike SIms when you try converting your preferred lol
Shareholders bailing out of PCTL as news about the Auctus response sweeps across the country
20. Denied. Further answering, Auctus is without information sufficient to admit or deny the date PCT learned that Auctus had exercised its rights under the Warrant. Further answering, Auctus states that it attempted to exercise the Warrant for 39,339,900 shares on December 10, 2021, but that, in breach of its obligations under the Warrant, PCT did not have sufficient shares in reserve. Further answering, on December 14, 2021, with the knowledge and consent of PCT, Auctus exercised its rights under the Warrant for 2,548,461 shares.
They were trying to jailbreak 40 million shares, but settled for 2.5 million? I hope Auctus could allege a criminal conspiracy to defraud them of their rights and benefits resulting in Gary’s arrest and removal
What do shareholders think of this?
Thanks for posting. It’s exactly as anticipated. Auctus never agreed, insufficient shares available, floorless convertible, jury trial, proved damages. Next chapter; PCTL will be forced to abide to Auctus pretrial demands or risk punitive damages bankrupting this jalopy. I hope Auctus demands include Gary’s resignation
Unless one is a member of Pacer, not sure links work.
So heres the converted text below.. may be some grammatical errors due to the conversion
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS
Civ. A. No. 1:22-CV-10053-WGY
ANSWER AND COUNTERCLAIMS
The defendant, Auctus Fund, LLC ("Auctus") answers the Complaint of Plaintiff PCT, LTD ("PCT") as follows.
PARTIES
1. Admitted.
2. Auctus is without information sufficient to admit or deny the allegations contained within paragraph 2.
3. Admitted.
4. Admitted to the extent that Auctus currently owns shares of PCT common stock.
Further answering, Auctus states that it still holds a Warrant for the purchase of a certain number of additional shares of PCT common stock ("Warrant") and that it is currently a creditor of PCT as a result of PCT's failure to honor the attempted exercise by Auctus of its rights under the Warrant. Auctus is therefore not a "former creditor" of PCT.
JURISDICTION AND VENUE
5. Denied. Auctus denies that the amount in controversy, as determined by the Complaint, exceeds $75,000, and therefore denies that the Court has subject matter jurisdiction over this matter.
6. Admitted.
7. Admitted.
8. Admitted.
FACTUAL ALLEGATIONS
9. Admitted.
10. Admitted.
11. Denied. Further answering, Auctus states that the Conditional Settlement Agreement ("Settlement Agreement") did not resolve, release or otherwise dispose of the rights of Auctus under the Warrant.
12. Denied in that the Settlement Agreement has additional provisions and further answering that the terms of the Settlement Agreement speak for themselves.
13. Denied. Further answering, Auctus states that the Mutual Release did not release any "rights" and further that the release language contained in the Mutual Release was limited to the "open dispute" between PCT and Auctus, which was a dispute regarding only the Note.
14. Denied. The terms of the Settlement Agreement speak for themselves. Further answering, contrary to the assertion of PCT, the Settlement Agreement does not state that the Mutual Release shall be signed "immediately" upon the receipt by Auctus of the final payment by PCT.
15. Admitted.
16. Admitted.
17. Denied. Auctus executed the Mutual Release and provided the same to PCT on February 4, 2022.
18. Denied.
19. Denied. Further answering, Auctus states that the Settlement Agreement did not resolve, release or otherwise dispose of the rights of Auctus under the Warrant.
20. Denied. Further answering, Auctus is without information sufficient to admit or deny the date PCT learned that Auctus had exercised its rights under the Warrant. Further answering, Auctus states that it attempted to exercise the Warrant for 39,339,900 shares on December 10, 2021, but that, in breach of its obligations under the Warrant, PCT did not have sufficient shares in reserve. Further answering, on December 14, 2021, with the knowledge and consent of PCT, Auctus exercised its rights under the Warrant for 2,548,461 shares.
21. Denied.
22. Denied.
23. Denied.
24. Denied.
25. Denied.
26. Admitted only to the extent PCT made a written demand and that PCT stated that it would not permit Auctus to exercise the Warrant for any additional shares of PCT common stock going forward. Otherwise denied. Further answering, PCT sought to have Auctus execute a form of Mutual Release that differed from the Mutual Release attached to the Settlement
Agreement. Further answering, Auctus states that Exhibit A to the Complaint does not include a true and accurate copy of the Settlement Agreement.
27. Admitted only to the extent that PCT made a demand on Auctus. Otherwise denied. Further answering, Auctus states that the Demand speaks for itself. Further answering, Auctus disputes that the Mutual Release contained an obvious scrivener's error.
28. Auctus admits only that it has not returned any stock to PCT. Auctus denies that it has ignored the Demand. Auctus denies that it obtained any stock wrongfully or fraudulently, denies that the Warrant is invalid and denies that it has any obligation to return any stock to PCT. Further answering, on February 4, 2022, Auctus delivered to PCT the executed form of Mutual Release attached to the Settlement Agreement.
29. Denied.
30. Denied.
COUNT ONE
(Breach of Contract)
31. Auctus reasserts and incorporates by reference its responses to all of the preceding paragraphs as if fully set forth herein.
32. Denied.
33. Denied to the extent that PCT is now claiming that any rights Auctus holds under the Warrant were released as part of the Settlement Agreement.
34. Denied.
35. Auctus is without information sufficient to admit or deny PCT's reasoning for entering into the Settlement Agreement or agreeing to the PCT Settlement Obligations.
36. Denied. Auctus executed the Mutual Release and provided the same to PCT on February 4, 2022.
37. Denied. Further answering, Auctus executed the Mutual Release and provided
the same to PCT on February 4, 2022.
38. Denied.
39. Denied. Answering further, Auctus executed the Mutual Release and provided the same to PCT on February 4, 2022.
COUNT TWO
(Breach of Implied Covenant of Good Faith and Fair Dealing)
40. Auctus reasserts and incorporates by reference its responses to all of the preceding paragraphs as if fully set forth here.
41. Paragraph 41 states a legal conclusion to which no answer is required. Denied to the extent that PCT alleges Auctus violated any covenant of good faith or fair dealing and to the extent PCT alleges that Auctus engaged in any conduct that deprived PCT of any benefits.
42. Denied.
43. Denied. Auctus executed the Mutual Release and provided the same to PCT on February 4, 2022. Answering further, Auctus states that the Settlement Agreement did not resolve, release or otherwise dispose of any rights of Auctus under the Warrant. Further answering, Auctus denies that its rights under the Warrant fall within the scope of the Mutual Release and admits that it claims that it has maintained all of its rights under the Warrant.
44. Denied.
45. Denied.
46. Denied.
COUNT THREE
(Reformation of Mutual Release)
47. Auctus reasserts and incorporates by reference its responses to all of the preceding paragraphs as if fully set forth here.
48. Denied in that the Settlement Agreement has additional provisions and further answering that the terms of the Settlement Agreement speak for themselves.
49. Denied.
50. Denied in that the Settlement Agreement has additional provisions and further answering that the terms of the Settlement Agreement speak for themselves. Admitted to the extent that the language of the Settlement Agreement speaks for itself.
51. Denied.
52. Denied.
53. Admitted to the extent that PCT provided Auctus with a revised Mutual Release.
Otherwise denied.
54. Denied. Further answering, paragraph 54 contains conclusions of law to which no
answer is required.
COUNT FOUR
(Fraud)
55. Auctus reasserts and incorporates by reference its responses to all of the preceding paragraphs as if fully set forth here.
56. Denied.
57. Denied.
58. Denied.
59. Admitted to the extent that Standard Registrar honored the exercise by Auctus of its rights under the Warrant for 2,548,461 shares. Denied as to the value of the shares in that the value constantly fluctuates.
60. Denied.
61. Denied.
COUNT FIVE
(Conversion)
62. Auctus reasserts and incorporates by reference its responses to all of the preceding paragraphs as if fully set forth here.
63. Denied. Answering further, Auctus states that the transfer to Auctus of 2,548,461 shares of PCT common stock was authorized.
64. Denied.
65. Denied.
66. Denied.
67. Denied.
COUNT SIX
(Unjust Enrichment)
68. Auctus reasserts and incorporates by reference its responses to all of the preceding paragraphs as if fully set forth here.
69. Admitted only to the extent that Auctus received 2,548,461 shares of PCT common stock. Otherwise denied.
70. Denied.
71. Denied.
72. Denied.
73. Denied.
AFFIRMATIVE DEFENSES
1. The Court lacks subject matter jurisdiction over PCT's claims.
2. The Complaint fails to state a claim upon which relief may be granted.
3. PCT has waived its claims related to the Warrant.
4. PCT is estopped from asserting its claims related to the Warrant.
5. PCT is seeking to recover lost profits or damages that are completely speculative in nature.
6. PCT has failed to state with particularity the circumstances constituting fraud as required by Federal Rule of Civil Procedure 9(b).
7. Auctus is discharged of all liability because it has fully performed and discharged all of its duties under the Settlement Agreement, including but not limited to, providing PCT with an executed copy of the Mutual Release.
8. Auctus acted in good faith by exercising its rights under the Warrant, based on the fact that the Warrant was not explicitly released by the Settlement Agreement or Mutual Release, and the release of the Warrant was never discussed at any point during the settlement negotiations.
COUNTERCLAIMS OF AUCTUS
Auctus asserts the following counterclaims:
JURISDICTION
1. The counterclaim plaintiff, Auctus Fund, LLC ("Auctus"), brings these counterclaims in response to the Complaint brought by counterclaim defendant PCT, LTD ("PCT") against Auctus.
FACTS
2. On March 13, 2019 Auctus entered into a Securities Purchase Agreement ("Purchase Agreement") with PCT for the purchase of a Convertible Promissory Note ("Note") from PCT in the original principal amount of $75,000. PCT also issued a warrant to Auctus for the purchase of a certain number of shares of PCT common stock ("Warrant").
3. On October 16, 2019, Auctus notified PCT that it was in default under the Note.
4. After negotiations between PCT and Auctus, the parties entered into a Conditional Settlement Agreement ("Settlement Agreement") dated October 26, 2020 in order to resolve PCT's default under the Note.
5. At no point in time during settlement negotiations did PCT and Auctus discuss the release or discharge of the Warrant as part of the Settlement Agreement.
6. Neither the Settlement Agreement nor the Mutual Release executed by PCT and Auctus in connection with the Settlement Agreement refer in any way to the Warrant.
7. The Settlement Agreement and Mutual Release do not release, resolve or otherwise dispose of any rights of Auctus under the Warrant.
8. On December 10, 2021, Auctus attempted to exercise its rights under the Warrant to acquire 39,339,900 shares of common stock of PCT.
9. PCT had an obligation to reserve sufficient shares of common stock of PCT such that Auctus could exercise its rights under the Warrant.
10. On December 13, 2021, Auctus was advised by Standard Registrar and Transfer Company that PCT had failed to reserve sufficient shares of common stock for the exercise by Auctus of its rights under the Warrant to obtain 39,339,900 shares of common stock of PCT.
11. On December 14, 2021, Auctus exercised its rights under the Warrant to acquire 2,548,461 shares of common stock of PCT. The exercise by Auctus of its rights under the Warrant to acquire 2,548,461 shares of common stock of PCT was consented to and approved by PCT.
12. PCT has failed to reserve adequate shares of common stock for Auctus to exercise its rights under the Warrant.
13. PCT has refused to honor the exercise by Auctus of its rights under the Warrant.
14. PCT has asserted that Auctus released its rights under the Warrant.
15. PCT has asserted that Auctus wrongfully attempted to exercise its rights to acquire shares of common stock of PCT.
16. PCT has asserted that Auctus wrongly exercised its rights to acquire shares of common stock of PCT.
17. Auctus asserts that PCT has breached the Warrant by failing to reserve adequate shares of common stock.
18. Auctus asserts that PCT has breached the Warrant by failing to honor the attempted exercise by Auctus of its rights under the Warrant to acquire 39,339,900 shares of common stock of PCT.
19. Auctus asserts that it rightfully obtained 2,548,461 shares of common stock of
PCT.
20. Auctus asserts that it has not released any of its rights under the Warrant and that it has maintained all of its rights under the Warrant.
21. Auctus delivered an executed Mutual Release to PCT on February 4, 2022 and has completed all of its obligations under the Settlement Agreement.
Counterclaim Count One Declaratory Judgment [28 U.S. Code §2201)
22. Auctus repeats and realleges the allegations contained in Counterclaims paragraphs 1 through 21 as though fully set forth herein.
23. PCT asserts that Auctus has waived any rights it held under the Warrant as part of the Settlement Agreement and Mutual Release.
24. Auctus disputes that it has released any of its rights under the Warrant, and asserts that it maintains all of its rights under the Warrant.
25. An actual controversy therefore exists between Auctus and PCT about whether the Settlement Agreement and Mutual Release released any rights of Auctus under the Warrant.
26. Pursuant to 28 U.S. Code §2201, Auctus is entitled to a declaration that the Settlement Agreement and Mutual Release did not resolve, release or otherwise dispose of any rights of Auctus under the Warrant and that Auctus is entitled to retain the 2,548,461 shares of PCT common stock it acquired pursuant to its exercise of rights under the Warrant.
Counterclaim Count Two Breach of Contract
27. Auctus repeats and realleges the allegations contained in Counterclaims paragraphs 1 through 26 as though fully set forth herein.
28. Auctus entered into the Settlement Agreement with PCT, for good and valuable consideration, in order to resolve disputes relating to the Note.
29. The Settlement Agreement and Mutual Release did not resolve, release or otherwise dispose of any rights of Auctus under the Warrant.
30. PCT has refused to honor the rights of Auctus under the Warrant and has breached the Warrant by failing to reserve an adequate number of shares of common stock of PCT for Auctus to exercise its rights under the Warrant.
31. PCT breached the Warrant by not permitting Auctus to exercise its rights under the Warrant on December 10, 2021 to acquire 39,339,900 shares of common stock of PCT.
32. By refusing to honor the exercise by Auctus of its rights under the Warrant, PCT has caused Auctus to incur substantial damages.
33. By reason of the foregoing, Auctus is entitled to an award of compensatory and consequential damages, together with attorneys' fees, costs and expenses.
JURY DEMAND
Auctus demands a trial by jury on all issues, claims and defenses so triable.
DEMAND FOR RELIEF
WHEREFORE, Auctus prays that the following relief and judgment be entered:
1. That judgment be entered in favor of Auctus and against PCT on all claims asserted by PCT in its Complaint.
2. That judgment be entered in favor of Auctus and against PCT on all claims asserted by Auctus in its Counterclaim.
3. That judgment be entered in favor of Auctus and against PCT under Count I of the Counterclaim of Auctus, declaring that the Settlement Agreement and Mutual Release did not resolve, release or otherwise dispose of any rights of Auctus under the Warrant and that Auctus is entitled to retain the 2,548,461 shares of PCT common stock it acquired pursuant to its exercise of rights under the Warrant.
4. That judgment be entered in favor of Auctus and against PCT under Count II of the Counterclaim of Auctus and that Auctus be compensated for its compensatory and consequential damages to be proven at trial.
5. That Auctus be awarded its attorneys' fees, costs and expenses.
6. That Auctus be awarded its costs and such other relief to which it may be entitled at law or in equity and to which this Court deems just and proper.
Respectfully submitted, AUCTUS FUND, LLC
By its attorneys:
Isl Charles R. Bennett Charles R. Bennett (BBO No. 037380) William R. Moorman (BBO No. 548593) MURPHY & KING, P.C.
28 State Street, Suite 3101
Boston, Mass. 02109
(617) 423-0400
cbennett((1)murphvking.com wmoorman(ii>1nurphyking.com
Dated: June 22, 2022
CERTIFICATE OF SERVICE
I certify that this document, filed through the CM/ECF system, will be sent electronically to the registered participants as identified on the NEF and paper copies will be sent to those indicated as non-registered participants on June 22, 2022.
Isl Charles R. Bennett
Charles R. Bennett
810855
Is a Ethiopia company making a Cash Infusion too? Chuckles what a Sham this pos is
N, is the C&P from latest court date? Can u post link please? tia
“5 pennies” or .0005?
Incorrect once again
Chuckles, the only Infusion is more shares
What’s the 4th of July picnic going to produce?
majic water?
Really 8M infusion from LeadGreen?
How do you know this?
Seems to me it’s made up bullshit.
Always nice to post things based on DD
Sheesh
If over 100,000,000 warrants exercisable at $0.00035 were wrongfully blocked from exercise, especially back when PCTL shares were trading much higher, then there seems to potentially be a mountain of problems ahead for PCT and its shareholders
lolol. looks great.
Followers
|
605
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
200739
|
Created
|
05/29/18
|
Type
|
Free
|
Moderators jimr1717 namtae thegreencandle |
Our products (equipment) and solutions (Hydrolyte® and Catholyte Free®) are designed to take an environmentally conscious approach to combat the spread of infectious disease in the healthcare and Cleaning/Sanitation industries, as well as contributing to the sustainability of global natural resources in the agriculture markets.
Our technology produces an effective pre-determined PPM Hypochlorous Acid (HOCl) solution that is created through an electrolytic process called Electro-Chemical Activation (ECA). It occurs by temporarily changing the makeup of water, bypassing weak salt brine through an electrolytic cell, and temporarily changing the properties of the salt water into a powerful oxidizing agent, exhibiting highly effective antimicrobial properties.
Many billions of dollars a year are spent by individuals, organizations, and the health care system to treat people who get infectious diseases caused by microbes including bacteria, viruses, and fungi. With the advent of adaptive and ever more dangerous microorganisms called “superbugs”, the danger of acquiring life-threatening infections is real and growing. This danger affects everyone anytime they are in space where people gather, any microbe contaminating that space is a possible source of infection. With American’s spending 20 or more hours a day indoors, much of it in spaces that are not cleaned and sanitized/ disinfected properly, the threat of infection is constant, growing, and dangerous, particularly to our vulnerable populations of the very young, elderly and infirm.
Infectious diseases were associated with an economic burden of over $120 billion in the U.S. in 2014. Antibiotic-resistant infections cost Americans $20 billion in direct medical costs and $35 billion in lost productivity in 2014. A particularly acute problem is Hospital Acquired Infections (HAIs) which are increasingly hard to kill or treat effectively. As a result, doctors struggle to contain, fight and cure increasingly antibiotic-resistant infections such as MRSA, and C. Diff. The more antibiotics, medicines, pesticides and disinfectants are used to kill them, the quicker the microorganisms adapt, becoming ever stronger and more drug-resistant. Researchers estimate that, if the U.S. could reduce the number of hospital-acquired infections by 20%, healthcare providers would save nearly $7 billion per year. Insurance companies are beginning to deny coverage for treatment of HAIs, forcing hospitals to self-insure. This will create an immense financial and risk-management burden on hospitals, long-term medical, rehabilitation, and assisted living facilities.
Overcoming the problem of microbial contamination and infectious disease can be straightforward. It requires proper products, equipment, protocols, education, and training for comprehensive and reliable cleaning, sanitizing, and disinfecting solutions.PCT Corp. offers these with its comprehensive “Green Cleaning” and Infection Control Systems. Infectious microbes cannot develop resistance to the cleaning and sanitizing products PCT Corp. uses and they are much less toxic to humans or pets than traditional agents such as bleach and ammonia.
The products are used through a commercially-ready, patented, integrated product and technology solution for total facility cleaning and sanitizing. This system and solution, The PCT Annihilyzer® Infection Control System, was specifically designed for use in hospitals, assisted living and nursing homes, and other large facilities. In various configurations, the solution system can be deployed in urgent care centers, medical, dental, and veterinary practices, and other health care facilities. A complete and custom turn-key cleaning, sanitizing, and disinfection program solution can be provided to each facility. It is also adaptable to deployment in schools, prisons, hotels, and many other facilities.
PCT has launched a major marketing and sales effort in the hospital facilities market and The PCT Annihilyzer® System has now been deployed in several hospitals in the eastern U.S.
Ticker Symbol:PCTL
4235 Commerce Street. Little River, SC 29566
Phone: 843-390-7900 Fax: 843-390-2327
Email: admin@pctl.com
***Last Reported Share Structure***
As of 12/30/21
Authorized: 1,000,000,000
Outstanding Shares: 790,924,690
Float: 525,421,556
https://www.otcmarkets.com/stock/PCTL/overview
https://www.otcmarkets.com/stock/PCTL/profile
https://www.otcmarkets.com/stock/PCTL/quote
https://www.otcmarkets.com/stock/PCTL/disclosure
Nano-Catholyte treated oil on its way to an oil refinery
Hospital-acquired infections (HAI) — also known as a nosocomial infection — is an infection that is contracted from the environment or staff of a healthcare facility. It can be spread in the hospital environment, nursing home environment, rehabilitation facility, clinic, or other clinical settings. In the United States, the Centers for Disease Control and Prevention estimated roughly 1.7 million hospital-associated infections, from all types of microorganisms, including bacteria and fungi combined, cause or contribute to 99,000 deaths each year.
Our goal is to provide solutions to this issue, by outfitting a healthcare setting with the technology and guidance needed to effectively get the job done - all through a dedicated partnership to prevent and eradicate the spread of infectious disease.
Oil and Gas:
Waste Water Treatment
Our system helps to decontaminate “frac” water for reuse in the fracking process, saving the industry millions of dollars and preserving the world’s water supply. Some of the many benefits of our system/process include: Elimination of highly toxic chemicals currently used for decontamination, reduced negative environmental impact, reduced recovery costs and potentially opening new areas for oil and gas retrieval.
Turning “Sour” Crude Oil to “Sweet”
In other areas in the gas and oil industry that presents a challenge is in treating existing wells for the presence of H2S of hydrogen sulfide. H2S is a large and growing problem in the industry, due to its continued introduction of bacteria in the fracking process. H2S causes increased production costs. Our solutions reduce those costs and reduce the environmental impact.
Agriculture:
In the agriculture world, through USDA grants and multiple studies by universities around the world, Hypochlorous acid solutions have been tested and proven effective against yield-reducing crop pathogens in post-harvest applications to include sanitizing at point of harvest, point of packing and points of sale.
We are hoping to help stop these crop-devastating pathogens with our hypochlorous solutions that are known to be environmentally responsible and designed to improve and maintain crop yields, to produce a healthier overall harvest.
School Systems:
Dedicated to the success of students, schools are faced with a multitude of challenges to reach their goal of providing a solid education and an environment for healthy growth. To add to the list of responsibilities of school administrators, the battle of keeping absenteeism down, preventing the spread of infectious disease and keeping a clean environment bears a heavy load. Not only are the traditional cleaning products losing their effectiveness - thus allowing drug/antimicrobial resistant pathogens to wreak havoc - they are also polluting the indoor air with volatile organic compounds (VOCs) that are known to cause respiratory-related issues, headaches and other ailments.
By providing daycare facilities, school systems and universities with a better alternative to poisonous, caustic chemical cleaning/antimicrobial agents, we’re providing a more productive environment. Not only are you killing germs with a product that eradicates them completely - keeping them from becoming resistant - you’re doing so with a product that doesn’t cause harm to the user, students or faculty.
Hotel and Tourism:
Similar to the healthcare environment, the hotel and tourism industry (i.e resorts, airports, cruise ships, etc.) are subject to communicable diseases. In the healthcare market, they are referred to as Hospital-Acquired Infections/Healthcare-Associated Infections (HAIs) and in the hotel and tourism industry, they are known as Community-Acquired Infections. With as many different people traveling through these areas, from all sorts of countries and carrying various types of ailments or pathogens with them, consider the potential for an uncontrollable spread of these germs.
Outbreaks are typically caused by lack of proper processes and/or a failing product. Our ECA technology is designed to help anyone in the industry to get a grip on the issue and succeed at their main goal: providing an awesome experience for their guests.
Food Service/Production:
Our sanitizer strength solution meets the requirement of the FDA and USDA, to be a non-rinse sanitizing agent. In the world of dealing with food, why not use a product that actually kills food-borne pathogens - without containing any toxic chemicals that would harm the quality of the product?
Whether you’re dealing with meat, poultry or just need to maintain a facility’s defense against Salmonella/E. coli, contact us about using our solutions
Forget harsh, toxic chemicals. Our process only requires salt, water and electricity to produce two products –a chlorine-based antimicrobial agent and an excellent degreasing cleaner.
Our technology produces an effective variable PPM hypochlorous acid solution that is created through an electrolytic process called Electro-Chemical Activation (ECA). It occurs by temporarily modifying the properties of water, by passing weak salt brine through an electrolytic cell and temporarily changing the properties of the salt water into a powerful oxidizing agent exhibiting highly effective antimicrobial properties.
Catholyte or sodium hydroxide, is an aqueous solution that is the natural byproduct of the electrolysis process, and is used to reduce microbe contamination and soil loads that can harbor germs on hard surfaces.
Catholyte is also a very effective degreaser and is a great option to safely clean floors without hazardous fumes, thus improving indoor air quality.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |